Rosiglitazone/metformin
ApprovedSmall molecule
GSKRosiglitazone/metformin is one of 70 small molecule programs targeting Type 2 Diabetes Mellitus. It is currently in Approved.
2
Indications
3
Total Trials
0
Active Trials
69
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
676 competitors in Type 2 Diabetes Mellitus
#DrugCompanyPhaseTrials
1Rosiglitazone/metformin
GSKApproved
Byetta
AstraZenecaPreclinical
Insulin 320
Novo NordiskPreclinical
NOVOLIN R
Novo NordiskPreclinical
Adenocard
AstellasPreclinical
Dostinex
PfizerPreclinical
Golytely
BayerPreclinical
Myrbetriq
AstellasPreclinical
Lantus
SanofiPreclinical
Lixisenatide
SanofiPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Safety and Efficacy1 trial
Diabetes Mellitus1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Rosiglitazone/metformin. EMBL-EBI & Wellcome Sanger Institute.
- [4]